Gravity-1(YL-1) launch vehicle completed its maiden flight from the Yellow Sea near Haiyang City, Shandong Province, on January 11, 2024, this mission successfully launched three Yunyao satellites into their 500 km or...Gravity-1(YL-1) launch vehicle completed its maiden flight from the Yellow Sea near Haiyang City, Shandong Province, on January 11, 2024, this mission successfully launched three Yunyao satellites into their 500 km orbit. The YL-1 has a performance of 4.2 tons for 500 km sun-synchronous orbit and 6.5 tons for low Earth orbit. The success of YL-1 has further enriched China's launch vehicle spectrum, and will facilitate the launch of medium and large satellites and satellite constellations. In this paper, the flight ballistic solution of YL-1 is introduced. The flight trajectory consists of seven flight segments. The trajectory design comprehensively considered the characteristics and safety requirements of the vehicle to achieve effective utilization of the performance. Through comparative analysis of the flight trajectory and the predicted trajectory, the result confirmed that the flight trajectory was consistent with the design results, the design methodology was correct, and the flight test met the expected requirements. Subsequently, the vehicle will be employed for commercial application launch services.展开更多
On January 11, 2024, the Gravity-1 launch vehicle successfully carried out its maiden flight from a mobile sea platform off the coast of Haiyang in Shandong Province, sending three meteorological satellites, Yunyao-1 ...On January 11, 2024, the Gravity-1 launch vehicle successfully carried out its maiden flight from a mobile sea platform off the coast of Haiyang in Shandong Province, sending three meteorological satellites, Yunyao-1 satellite No. 18-20, into an orbit about 500 km above the ground. The successful debut flight of Gravity-1 broke many records such as the world's largest solid launch vehicle, the first sea-launched strap-on launch vehicle in the world, with the maximum carrying capacity of current commercial launch vehicle in China. This flight marked a big step in the field of China's commercial space launch application. A new breakthrough has been made, which is of great significance for further expanding China's diversified and large-scale launch capabilities of medium and low orbit satellites, expanding the spectrum of China's launch vehicle types, and promoting the development of space science.展开更多
目的:探究血清甘油三酯-葡萄糖(TyG)指数、摄食抑制因子-1(nesfatin-1)、视黄醇结合蛋白4(RBP4)联合预测糖尿病视网膜病变(DR)的价值,为DR早期预测提供支持。方法:回顾性分析。收集2022-02/2023-12我院接诊的2型糖尿病(T2DM)患者164例...目的:探究血清甘油三酯-葡萄糖(TyG)指数、摄食抑制因子-1(nesfatin-1)、视黄醇结合蛋白4(RBP4)联合预测糖尿病视网膜病变(DR)的价值,为DR早期预测提供支持。方法:回顾性分析。收集2022-02/2023-12我院接诊的2型糖尿病(T2DM)患者164例的临床资料,按照眼底检查结果分为DR组43例(其中增殖性DR 19例,非增殖性DR 24例),不合并DR的T2DM组121例。入院后记录患者基本资料,检查血清TyG指数、nesfatin-1、RBP4水平。结果:DR组病程长于T2DM组,空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、低密度脂蛋白及TyG指数、RBP4水平高于T2DM组,高密度脂蛋白、nesfatin-1水平低于T2DM组(均P<0.001)。多因素Logistic回归分析可知,T2DM病程(OR=1.338,95%CI:1.059-1.690)、糖化血红蛋白(OR=5.065,95%CI:1.659-15.470)、低密度脂蛋白(OR=12.715,95%CI:2.385-67.790)、TyG指数(OR=23.057,95%CI:2.936-181.073)、RBP4(OR=1.319,95%CI:1.028-1.692)是T2DM患者发生DR的危险因素,nesfatin-1(OR=0.007,95%CI:0.003-0.016)为保护因素。绘制ROC曲线显示,TyG指数、nesfatin-1、RBP4均对T2DM患者并发DR具有一定预测价值,曲线下面积(areas under curve,AUC)分别为0.804、0.878、0.738,各指标联合预测时AUC为0.946,预测敏感度为83.72%、特异度为92.56%。增殖性DR患者TyG指数、RBP4水平高于非增殖性DR患者,nesfatin-1水平低于非增殖性DR患者(均P<0.05)。Spearman相关性分析显示,TyG指数、RBP4水平与DR病情程度呈正相关,nesfatin-1水平与DR病情程度呈负相关(r_(s)=0.557、0.392、-0.359,均P<0.05)。Pearson相关分析显示,T2DM并发DR患者TyG指数与nesfatin-1水平呈负相关,与RBP4水平呈正相关,nesfatin-1与RBP4水平呈负相关(r=-0.486、0.538、-0.592,均P<0.05)。结论:血清TyG指数、nesfatin-1、RBP4水平与DR发病风险及病情程度有关,可作为DR早期预测的标志物,且联合预测效能更好。展开更多
文摘Gravity-1(YL-1) launch vehicle completed its maiden flight from the Yellow Sea near Haiyang City, Shandong Province, on January 11, 2024, this mission successfully launched three Yunyao satellites into their 500 km orbit. The YL-1 has a performance of 4.2 tons for 500 km sun-synchronous orbit and 6.5 tons for low Earth orbit. The success of YL-1 has further enriched China's launch vehicle spectrum, and will facilitate the launch of medium and large satellites and satellite constellations. In this paper, the flight ballistic solution of YL-1 is introduced. The flight trajectory consists of seven flight segments. The trajectory design comprehensively considered the characteristics and safety requirements of the vehicle to achieve effective utilization of the performance. Through comparative analysis of the flight trajectory and the predicted trajectory, the result confirmed that the flight trajectory was consistent with the design results, the design methodology was correct, and the flight test met the expected requirements. Subsequently, the vehicle will be employed for commercial application launch services.
文摘On January 11, 2024, the Gravity-1 launch vehicle successfully carried out its maiden flight from a mobile sea platform off the coast of Haiyang in Shandong Province, sending three meteorological satellites, Yunyao-1 satellite No. 18-20, into an orbit about 500 km above the ground. The successful debut flight of Gravity-1 broke many records such as the world's largest solid launch vehicle, the first sea-launched strap-on launch vehicle in the world, with the maximum carrying capacity of current commercial launch vehicle in China. This flight marked a big step in the field of China's commercial space launch application. A new breakthrough has been made, which is of great significance for further expanding China's diversified and large-scale launch capabilities of medium and low orbit satellites, expanding the spectrum of China's launch vehicle types, and promoting the development of space science.
文摘目的:探究血清甘油三酯-葡萄糖(TyG)指数、摄食抑制因子-1(nesfatin-1)、视黄醇结合蛋白4(RBP4)联合预测糖尿病视网膜病变(DR)的价值,为DR早期预测提供支持。方法:回顾性分析。收集2022-02/2023-12我院接诊的2型糖尿病(T2DM)患者164例的临床资料,按照眼底检查结果分为DR组43例(其中增殖性DR 19例,非增殖性DR 24例),不合并DR的T2DM组121例。入院后记录患者基本资料,检查血清TyG指数、nesfatin-1、RBP4水平。结果:DR组病程长于T2DM组,空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、低密度脂蛋白及TyG指数、RBP4水平高于T2DM组,高密度脂蛋白、nesfatin-1水平低于T2DM组(均P<0.001)。多因素Logistic回归分析可知,T2DM病程(OR=1.338,95%CI:1.059-1.690)、糖化血红蛋白(OR=5.065,95%CI:1.659-15.470)、低密度脂蛋白(OR=12.715,95%CI:2.385-67.790)、TyG指数(OR=23.057,95%CI:2.936-181.073)、RBP4(OR=1.319,95%CI:1.028-1.692)是T2DM患者发生DR的危险因素,nesfatin-1(OR=0.007,95%CI:0.003-0.016)为保护因素。绘制ROC曲线显示,TyG指数、nesfatin-1、RBP4均对T2DM患者并发DR具有一定预测价值,曲线下面积(areas under curve,AUC)分别为0.804、0.878、0.738,各指标联合预测时AUC为0.946,预测敏感度为83.72%、特异度为92.56%。增殖性DR患者TyG指数、RBP4水平高于非增殖性DR患者,nesfatin-1水平低于非增殖性DR患者(均P<0.05)。Spearman相关性分析显示,TyG指数、RBP4水平与DR病情程度呈正相关,nesfatin-1水平与DR病情程度呈负相关(r_(s)=0.557、0.392、-0.359,均P<0.05)。Pearson相关分析显示,T2DM并发DR患者TyG指数与nesfatin-1水平呈负相关,与RBP4水平呈正相关,nesfatin-1与RBP4水平呈负相关(r=-0.486、0.538、-0.592,均P<0.05)。结论:血清TyG指数、nesfatin-1、RBP4水平与DR发病风险及病情程度有关,可作为DR早期预测的标志物,且联合预测效能更好。
